The prognosis of adult acute myeloid leukemia (AML) remains poor, using the lengthy-term rate of survival under 50%. However, the present paradigms of treatment are altering via a better knowledge of the condition genetics and pathophysiology. Since 2017, eight new drugs happen to be authorized by the U.S. Fda to treat AML, such as the FLT3 inhibitors midostaurin and gilteritinib, the IDH inhibitors ivosidenib and enasidenib, the anti-CD33 monoclonal antibody gemtuzumab ozogamicin, liposomal daunorubicin and cytarabine, the hedgehog path inhibitor glasdegib and also the BCL-2 inhibitor venetoclax. Preclinical data shown the anti-leukemic effectiveness of venetoclax in AML and it is synergy when coupled with hypomethylating agents or chemotherapy agents. Numerous studies have shown the clinical advantage of venetoclax-based therapies in recently diagnosed AML, resulting in the current Food and drug administration approval of venetoclax in conjunction with hypomethylating agents or low-dose cytarabine for seniors with recently diagnosed AML. Herein, we concentrate on the role of single-agent BCL-2 inhibition in AML and evaluate the studies of venetoclax-based combination regimens and also the evolving mechanisms of resistance.